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Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used in 
patients during cardiac arrest and cardiogenic shock and is associated with increased survival rate1. 
Since mortality on ECMO is still rather high, SAVE (Survival after Veno-Arterial ECMO) score can be 
used to predict survival from refractory cardiogenic shock requiring ECMO2. 
Patients and Methods: We performed a retrospective analysis of 121 patients (78% male) who under-
went VA-ECMO implantation in our Department from January 2011 till November 2020 (Figure 1 and 
Table 1). 
Results: Median age was 58 years with 21% of patients older then 65 years. Median of ECMO duration 
was 6 days. The most common causes of cardiogenic shock were acute myocardial infarction and 
cardiomyopathy (53% and 37%, respectively) (Figure 2), and 37% patients were implanted during car-
diopulmonary resuscitation (eCPR). Overall survival on ECMO support was 59%, but in patients after 
CPR only 34%. Furthermore, of all patients, 34% were successfuly weaned and the rest who survived 
continued on advanced heart failure therapies (Figure 3), but overall survival in follow-up was only 
26%. Median SAVE score was -8 with significantly less negative values in patients younger than 65 and 
treated after 2015. Also, patients treated before 2015 had significantly higher values of creatinine, free 
hemoglobine and international normalized ratio (INR) and their survival rate was only 39%, in com-
parison to those who were implanted after 2015 whose survival rate was 62%. 
Figure 1. Number of venoarterial extracorporeal membrane oxygenation 
implantations from January 2011 to November 2020.
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Conclusion: Although results with ECMO support in cardiogenic shock in our Department improved throughout 10-years experi-
ence, they still exhibit high long-term mortality. Our observations reinforce the need for thorough assessment of each ECMO candi-
date, especially in respect to patient’s age, end-organ failure and SAVE score as key steps to ensure optimal outcomes.
TABLE 1. Clinical characteristics and laboratory values prior to 
venoarterial extracorporeal membrane oxygenation implantation.
Age, years (Mdn, IQR) 58 (49-64)
Gender male (N, %) 94 (78)
BMI, kg/m2 (Mdn, IQR) 27 (24-30)
Creatinine, qmol/L (Mdn, IQR) 130 (87-173)
Bilirubin, qmol/L (Mdn, IQR) 16 (10-34)
INR (Mdn, IQR) 1.2 (1.05-1.52)
NT-proBNP, ng/L (Mdn, IQR) 7654 (2834-15582)
TnT, ng/L (Mdn, IQR) 292 (43-2620)
LDH, U/L (Mdn, IQR) 755 (293-1817)
CRP, mg/L (Mdn, IQR) 20 (4-74)
SAVE score (Mdn, IQR) -8 (-12- -4)
ECMO, days (Mdn, IQR) 6 (3-10)
ECMO during CPR (N, %) 44 (37)
Figure 2. etiology of cardiogenic shock. 
 
CMP = cardiomyopathy; AMI = acute myocardial infarction
Figure 3. Outcomes of patients on venoarterial extracorporeal 
membrane oxygenation implantation.
LVAD = left ventricular assist device
Ten years of extracorporeal membrane oxygenation support at University Hospital Centre Zagreb
